TYSABRI 300 mg concentrate for solution for infusion

Patient Alert Card

This alert card contains important safety information that you need to be aware of before, during and after stopping treatment with Tysabri (natalizumab). Hard copies can be requested by contacting Biogen at [email protected] or by telephone on 0800 008 7401.

Physician Information and Management Guidelines for Patients with Multiple Sclerosis receiving TYSABRI Therapy

This guidance document has been developed for those physicians initiating and supervising TYSABRI in accordance with the conditions of the Marketing Authorisation of the drug.

For Healthcare Professionals

Treatment Continuation Form

This form should be read carefully before continuing TYSABRI treatment for more than 2 years.

Treatment Discontinuation Form

This form should be read carefully before discontinuing treatment with TYSABRI.

Treatment Initiation Form

This form should be read carefully before starting treatment with TYSABRI.

Send us feedback

If you would like to make a comment or send us feedback on this material, click here.